Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Locally Advanced or Metastatic Breast Cancer
and you are
over 18
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.

Provided treatments

  • Drug: Eribulin
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03027245. The sponsor of the trial is Eisai GmbH and it is looking for 400 volunteers for the current phase.
Official trial title:
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)